Eric Winer
#51,995
Most Influential Person Now
American doctor
Eric Winer's AcademicInfluence.com Rankings
Eric Winerphilosophy Degrees
Philosophy
#2874
World Rank
#4773
Historical Rank
Logic
#831
World Rank
#1380
Historical Rank
Download Badge
Philosophy
Why Is Eric Winer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Eric Winer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- Breast Cancer Treatment: A Review (2019) (2022)
- American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. (2005) (1736)
- Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer (2018) (1567)
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015) (1499)
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. (2016) (1113)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. (2002) (1006)
- Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. (2004) (958)
- Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. (2010) (912)
- Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. (1999) (902)
- Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. (2013) (900)
- CDK4/6 inhibition triggers anti-tumor immunity (2017) (836)
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) (820)
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015) (726)
- Web-based survey of fertility issues in young women with breast cancer. (2004) (689)
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma (2003) (687)
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014) (671)
- CNS metastases in breast cancer. (2004) (667)
- 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. (2003) (631)
- Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. (2001) (618)
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (616)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. (2014) (612)
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) (604)
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer (2008) (586)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (584)
- Adherence to therapy with oral antineoplastic agents. (2002) (572)
- Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. (2008) (571)
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† (2014) (566)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
- Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. (2001) (529)
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. (2010) (524)
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. (1993) (514)
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. (2014) (509)
- Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. (2014) (508)
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. (2008) (507)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer (2009) (499)
- Breast cancer. Clinical practice guidelines in oncology. (2009) (498)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (2015) (483)
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma (2002) (482)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (469)
- Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. (1998) (468)
- Adjuvant ovarian suppression in premenopausal breast cancer. (2015) (467)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study (2019) (464)
- Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. (2008) (460)
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network (2012) (459)
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. (2008) (439)
- Response and resistance to BET bromodomain inhibitors in triple negative breast cancer (2015) (437)
- HER2 and response to paclitaxel in node-positive breast cancer. (2007) (433)
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. (2012) (430)
- Triple-Negative Breast Cancer: Risk Factors to Potential Targets (2008) (430)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. (2006) (418)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2017) (405)
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (2018) (402)
- Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. (2005) (386)
- Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. (1997) (380)
- Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. (2001) (376)
- Brain Metastases: The HER2 Paradigm (2007) (370)
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. (2016) (370)
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2019) (368)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer (2006) (361)
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. (2003) (359)
- Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. (2008) (358)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? (2010) (349)
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018) (348)
- American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. (1999) (344)
- A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. (2012) (332)
- Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. (2001) (327)
- Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014) (324)
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. (2015) (320)
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. (2016) (317)
- 1st International consensus guidelines for advanced breast cancer (ABC 1). (2012) (308)
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. (2016) (301)
- Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. (1998) (301)
- Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. (2018) (297)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2019) (294)
- Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. (2003) (291)
- Quality of non-breast cancer health maintenance among elderly breast cancer survivors. (2003) (283)
- Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (277)
- Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. (2008) (274)
- Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. (2019) (271)
- Docetaxel administered on a weekly basis for metastatic breast cancer. (2000) (267)
- A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (2011) (265)
- Complications of axillary lymph node dissection for carcinoma of the breast (1998) (254)
- Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. (2014) (252)
- Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer (2007) (249)
- Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. (2016) (245)
- 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. (2002) (244)
- Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer (2013) (243)
- Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer (2012) (243)
- HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. (2004) (241)
- Primary care for survivors of breast cancer. (2000) (236)
- Weight gain in women diagnosed with breast cancer. (1997) (235)
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial (2020) (233)
- Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. (2004) (229)
- Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study (2003) (229)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. (2016) (228)
- Complementary and alternative medicine use among women with breast cancer. (2002) (228)
- Local therapy and survival in breast cancer. (2007) (227)
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy (2009) (226)
- Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. (2013) (224)
- Adjuvant chemotherapy in older women with early-stage breast cancer. (2009) (220)
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer (2016) (220)
- Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study (2007) (219)
- Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) (2017) (218)
- Protocol for the examination of specimens from patients with invasive carcinoma of the breast. (2009) (217)
- Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. (2015) (215)
- Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. (2007) (215)
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases (2019) (213)
- Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. (1997) (212)
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. (2016) (212)
- High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. (1992) (209)
- 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
- Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program (2017) (207)
- Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. (2011) (206)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- CDK4/6 inhibition in breast cancer: current practice and future directions (2018) (203)
- Why women gain weight with adjuvant chemotherapy for breast cancer. (1993) (201)
- ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer ( ABC 2 ) (2014) (201)
- Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. (2014) (198)
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients (2015) (194)
- Long‐term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer (2007) (193)
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab (2012) (192)
- American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. (2002) (189)
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. (2018) (184)
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. (2019) (183)
- A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 (2012) (183)
- The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care (2011) (182)
- Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. (2015) (180)
- TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (2008) (176)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival (2009) (172)
- Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. (2009) (169)
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. (2020) (167)
- Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. (2008) (166)
- The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™ (2007) (165)
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer (2016) (159)
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. (2018) (158)
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. (2013) (158)
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. (2010) (158)
- Cardiac toxicity from systemic cancer therapy: a comprehensive review. (2010) (157)
- Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. (2014) (157)
- Prevalence and mutational determinants of high tumor mutation burden in breast cancer (2019) (156)
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). (2015) (156)
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (156)
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases (2011) (154)
- Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. (2009) (153)
- Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 (2006) (152)
- Body image in recently diagnosed young women with early breast cancer (2013) (151)
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. (2021) (150)
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. (2014) (149)
- Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. (1999) (148)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (2006) (147)
- Informing clinical trial participants about study results. (2002) (147)
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer (2017) (142)
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. (2019) (141)
- Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. (2014) (141)
- Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. (2005) (141)
- Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer (2010) (141)
- Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). (2015) (140)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 (2017) (137)
- Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib (2011) (137)
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. (2018) (137)
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (2019) (136)
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies (2018) (136)
- VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy (2008) (134)
- Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. (2007) (133)
- Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. (2004) (132)
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. (2016) (130)
- Factors related to underuse of surveillance mammography among breast cancer survivors. (2006) (129)
- NCCN Practice Guidelines for Breast Cancer. (2000) (129)
- American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. (2011) (128)
- Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (2017) (127)
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. (2015) (127)
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer (2009) (127)
- The natural history of hormone receptor-positive breast cancer. (2012) (126)
- Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. (2006) (123)
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. (2021) (122)
- Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. (2006) (121)
- Phase II evaluation of thalidomide in patients with metastatic breast cancer. (2000) (119)
- Advances in adjuvant endocrine therapy for postmenopausal women. (2008) (117)
- Surveillance testing among survivors of early-stage breast cancer. (2007) (117)
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021) (117)
- Association between pharmaceutical involvement and outcomes in breast cancer clinical trials (2007) (115)
- Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (113)
- Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. (2010) (112)
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (111)
- Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
- KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) (2019) (110)
- Cancer pain survey: patient-centered issues in control. (1998) (110)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. (2002) (108)
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. (2021) (108)
- The effect of age on delay in diagnosis and stage of breast cancer. (2010) (107)
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. (2013) (107)
- Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer (2020) (106)
- Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. (2005) (98)
- Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. (2013) (97)
- Trastuzumab/chemotherapy combinations in metastatic breast cancer. (2002) (96)
- Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). (2016) (96)
- Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. (1999) (96)
- Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. (2016) (95)
- Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
- Predicting response and survival in chemotherapy-treated triple-negative breast cancer (2014) (94)
- Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. (2005) (91)
- GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays (2011) (90)
- Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases (2016) (89)
- Offering participants results of a clinical trial: sharing results of a negative study (2005) (89)
- American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. (2003) (89)
- PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer (2013) (88)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
- Menopausal-type symptoms in young breast cancer survivors. (2006) (88)
- Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. (2011) (87)
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma (2000) (86)
- Randomized trial of a physical activity intervention in women with metastatic breast cancer (2016) (86)
- Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance) (2016) (86)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer (2019) (85)
- International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. (2013) (84)
- Racial Differences in Definitive Breast Cancer Therapy in Older Women: Are They Explained by the Hospitals where Patients Undergo Surgery? (2009) (83)
- Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. (2012) (83)
- Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. (2010) (82)
- Involving family members in cancer care: focus group considerations of patients and oncological providers (2000) (82)
- Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis (2008) (82)
- Breast cancer presentation and diagnostic delays in young women (2014) (81)
- Do patients participating in clinical trials want to know study results? (2003) (81)
- Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. (2005) (80)
- Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. (2014) (80)
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. (2023) (80)
- Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
- Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. (2014) (79)
- Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. (2013) (79)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (78)
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2019) (77)
- Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer (2015) (77)
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. (2018) (76)
- Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (2014) (76)
- The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. (2004) (76)
- CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (2012) (75)
- Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. (2017) (75)
- EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT) (2007) (75)
- Fertility and menopausal outcomes in young breast cancer survivors. (2008) (75)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) (2016) (73)
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). (2014) (73)
- TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). (2020) (72)
- Breast Cancer Treatment. (2019) (72)
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer (2016) (71)
- Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea (2014) (71)
- Pre-counseling education materials for BRCA testing: does tailoring make a difference? (2002) (71)
- Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer (2020) (69)
- Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. (2007) (68)
- Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. (2008) (68)
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (67)
- Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. (2005) (66)
- New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors (2004) (66)
- Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors (2009) (66)
- Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. (2004) (66)
- Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design (2017) (66)
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) (2019) (65)
- Breast cancer survivors' perceptions of survivorship care options. (2012) (64)
- Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. (1994) (64)
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients (2016) (64)
- Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2013) (63)
- Time to diagnosis and breast cancer stage by race/ethnicity (2012) (63)
- Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. (2001) (63)
- Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. (2011) (62)
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
- Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial (1997) (61)
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (2016) (61)
- The ethical use of mandatory research biopsies (2011) (61)
- Pertuzumab: Optimizing HER2 Blockade (2013) (60)
- Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. (1990) (60)
- Invasive breast cancer. (2007) (60)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2019) (60)
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) (60)
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. (2020) (59)
- Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) (2015) (59)
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) (2016) (59)
- Genetic testing for susceptibility to breast cancer: findings from women's focus groups. (1997) (58)
- Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? (2018) (58)
- Liposomal anthracyclines for breast cancer. (2001) (58)
- A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases (2013) (58)
- Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (2019) (57)
- Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. (2003) (57)
- A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). (2016) (57)
- Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. (2006) (57)
- Cancer‐related communication between female patients and male partners scale: a pilot study (2006) (57)
- Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial (2010) (56)
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. (2019) (56)
- Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results (2015) (56)
- Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. (2017) (55)
- NCCN Task Force Report: breast cancer in the older woman. (2008) (55)
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases (2014) (55)
- Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. (2010) (54)
- Model program to improve care for a unique cancer population: young women with breast cancer. (2012) (54)
- Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy (2012) (54)
- Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer (2013) (54)
- The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy (2019) (53)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. (2020) (53)
- Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2 (2000) (52)
- Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes (1998) (52)
- Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer (2008) (52)
- Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). (2014) (51)
- New Combinations with Herceptin® in Metastatic Breast Cancer (2001) (51)
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2016) (51)
- Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. (2010) (50)
- Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer (2019) (50)
- Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer (2009) (50)
- Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. (1999) (50)
- Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance) (2017) (50)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer (2009) (50)
- Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer (2008) (49)
- Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. (1999) (49)
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. (2020) (48)
- Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer (2018) (48)
- Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). (2017) (48)
- Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. (2009) (47)
- High performance teamwork training and systems redesign in outpatient oncology (2013) (47)
- Phase I study of Doxil and vinorelbine in metastatic breast cancer. (1999) (47)
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer (2014) (47)
- Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. (2012) (47)
- Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. (2007) (47)
- Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
- Economic outcomes of breast cancer survivorship: CALGB study 79804 (2005) (46)
- Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (2012) (46)
- A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. (2009) (46)
- Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). (2017) (45)
- Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. (2006) (45)
- Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. (2021) (45)
- Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer (2019) (44)
- Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). (2013) (44)
- Breast cancer‐specific survival by age: Worse outcomes for the oldest patients (2018) (44)
- Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients (2011) (43)
- Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study (2019) (43)
- LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) (2021) (43)
- A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. (2011) (43)
- Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics (2012) (43)
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer (2015) (42)
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. (2019) (42)
- Brain Metastases : The HER 2 Paradigm (2007) (42)
- I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment. (2016) (42)
- Long-term complications of adjuvant chemotherapy for early stage breast cancer. (2004) (41)
- The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis (2016) (41)
- Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women (2010) (41)
- Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support (1999) (41)
- Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). (2016) (41)
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial (2021) (41)
- PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers (2016) (40)
- Ki 67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer : Results From the American College of Surgeons Oncology Group Z 1031 Trial ( Alliance ) (2016) (40)
- Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. (2007) (40)
- CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC) (2007) (40)
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? (2013) (40)
- Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? (2013) (39)
- Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis (2021) (39)
- Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy (2014) (39)
- Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (2020) (39)
- Applying a conceptual model for examining health‐related quality of life in long‐term breast cancer survivors: CALGB study 79804 (2008) (39)
- Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. (2008) (38)
- TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). (2020) (38)
- Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. (2018) (38)
- Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". (2019) (38)
- Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). (2014) (38)
- Sarcoidosis mimicking metastatic breast cancer. (2007) (37)
- Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study (2016) (37)
- On mammography--more agreement than disagreement. (2009) (36)
- Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) (2013) (36)
- Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer. (2010) (36)
- Survival Implications Associated with Variation in Mastectomy Rates for Early-Staged Breast Cancer (2012) (35)
- Perils of the Pathologic Complete Response. (2016) (35)
- Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. (1999) (35)
- Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901 (2014) (35)
- A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer (2018) (35)
- Outcomes following local therapy for early-stage breast cancer in non-trial populations (2011) (35)
- Factors Contributing to Patient Satisfaction with Breast Reconstruction Using Silicone Gel Implants (1996) (34)
- Quality‐of‐life research in patients with breast cancer (1994) (34)
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). (2015) (34)
- Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis (2016) (34)
- Attitudes, knowledge, risk perceptions and decision‐making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses (2003) (34)
- Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. (2014) (34)
- TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). (2017) (34)
- Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions (2007) (34)
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021) (34)
- Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. (2012) (34)
- CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). (2019) (34)
- Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. (2009) (33)
- TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. (2020) (33)
- The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer (2006) (33)
- Quality of life in long-term survivors of metastatic breast cancer. (2012) (33)
- Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) (2014) (33)
- Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. (2020) (32)
- Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? (2011) (32)
- Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. (2017) (32)
- Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 (2008) (32)
- Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (32)
- The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries (2007) (32)
- TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. (2011) (32)
- A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. (2020) (32)
- p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) (2011) (32)
- Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. (2007) (31)
- Racial differences in outcomes for patients with metastatic breast cancer by disease subtype (2015) (31)
- Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer (2018) (31)
- New cytotoxic agents and schedules for advanced breast cancer. (2001) (31)
- The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. (2012) (31)
- Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. (1995) (31)
- Oral 5-FU analogues in the treatment of breast cancer. (1998) (31)
- LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (30)
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. (2020) (30)
- Silicone controversy: a survey of women with breast cancer and silicone implants. (1993) (29)
- Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. (2015) (29)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (2015) (29)
- TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. (2019) (29)
- Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. (2008) (29)
- Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice (2013) (29)
- Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. (1992) (29)
- Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors (2015) (29)
- CMF revisited in the 21st century. (2012) (28)
- Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. (2015) (28)
- Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). (2014) (28)
- Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) (2018) (28)
- Overestimation of hereditary breast cancer risk. (1998) (28)
- Care in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast Cancer (2007) (28)
- Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. (2020) (27)
- PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling (2015) (27)
- Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer (2018) (27)
- Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. (2009) (27)
- Quality of life and symptoms in male breast cancer survivors. (2013) (27)
- Hormonal Therapy in Postmenopausal Women with Breast Cancer (2003) (27)
- Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. (2019) (26)
- Lymphopenia associated with adjuvant anthracycline/ taxane regimens. (2008) (26)
- Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) (2020) (26)
- Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review (2017) (26)
- Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. (2005) (26)
- Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907 (2013) (26)
- Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib (2020) (26)
- CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer (2022) (26)
- Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980 (2008) (26)
- Long-term risk perceptions of women with ductal carcinoma in situ. (2013) (26)
- A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. (2014) (25)
- Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. (2011) (25)
- Heterogeneity of breast cancer and implications of adjuvant chemotherapy (2008) (25)
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. (2009) (25)
- Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 (2006) (25)
- Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. (2008) (25)
- Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program (2015) (24)
- Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy (2005) (24)
- Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations (2007) (24)
- Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis (2013) (24)
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. (2013) (24)
- ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. (2020) (24)
- 397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer (2003) (24)
- The impact of sharing results of a randomized breast cancer clinical trial with study participants (2009) (24)
- Optimizing endocrine therapy for breast cancer. (2005) (23)
- Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer (2015) (23)
- Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) (2019) (23)
- IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). (2016) (23)
- Attitudes of patients with metastatic breast cancer toward research biopsies. (2013) (23)
- Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 (2021) (22)
- Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). (2012) (22)
- Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. (2016) (22)
- Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort (2015) (22)
- SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). (2012) (22)
- A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer (2013) (21)
- LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2020) (21)
- Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. (2009) (21)
- Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). (2012) (21)
- Follow-up care of patients with breast cancer. (2007) (21)
- Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. (2019) (21)
- Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ (2008) (21)
- Genomic Characterization of de novo Metastatic Breast Cancer (2020) (21)
- Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc (2015) (21)
- Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (2020) (20)
- Patterns of bone density evaluation in a community population treated with aromatase inhibitors (2012) (20)
- A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer (2020) (20)
- Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases (2020) (20)
- KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC). (2016) (20)
- A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. (2011) (20)
- HER2 or not HER2: that is the question. (2005) (20)
- Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer (2006) (20)
- Sharing study results with trial participants: time for action. (2009) (20)
- Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. (2015) (20)
- The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer (2021) (20)
- Homologous Recombination De fi ciency ( HRD ) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) (19)
- Defining success in neoadjuvant breast cancer trials (2014) (19)
- STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer (2022) (19)
- Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. (2006) (19)
- Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. (2013) (19)
- Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers (2016) (19)
- Fertility after breast cancer: questions abound. (2005) (19)
- Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2019) (19)
- Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment (2013) (19)
- Quality of life after bone marrow transplantation. (1994) (18)
- Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
- Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. (2014) (18)
- Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer (2020) (18)
- A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. (2016) (18)
- TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer (2016) (18)
- Aromatase inhibition in obese women: how much is enough? (2012) (18)
- Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer (2015) (18)
- Adjuvant chemotherapy in luminal breast cancers. (2011) (18)
- Survival benefit needed to undergo chemotherapy: Patient and physician preferences (2017) (18)
- Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
- PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer (2019) (17)
- HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182 (1999) (17)
- The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. (2016) (17)
- Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. (2019) (17)
- Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules (2006) (17)
- Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. (2010) (17)
- The role of socioeconomic status in adjustment after ductal carcinoma in situ (2010) (17)
- Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). (2015) (17)
- Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer (2013) (17)
- P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. (2011) (17)
- Testing for hereditary breast and ovarian cancer in the southeastern United States. (2000) (17)
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. (2008) (16)
- How we treat HER2-positive brain metastases (2021) (16)
- Beyond Anatomic Staging: Are We Ready to Take the Leap to Molecular Classification? (2005) (16)
- How well do standard prognostic criteria predict oncotype DX (ODX) scores (2007) (16)
- Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer (2015) (16)
- Modeling Risk of Breast Cancer and Decisions about Genetic Testing (1999) (16)
- Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. (2020) (16)
- De-escalating Breast Cancer Surgery-Where Is the Tipping Point? (2019) (16)
- Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. (2020) (15)
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer (2013) (15)
- Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC) (2018) (15)
- Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors (2019) (15)
- Standards for follow-up care of patents with breast cancer. (2005) (15)
- Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer (2017) (15)
- Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) (2009) (15)
- A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases (2019) (15)
- Male breast cancer networking and telephone support group: a model for supporting a unique population (2014) (15)
- Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
- Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. (2014) (15)
- Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast (2015) (14)
- Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. (2020) (14)
- PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (2017) (14)
- Patient Utilities for Advanced Cancer: Effect of Current Health on Values (2005) (14)
- A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. (2009) (14)
- Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. (2012) (14)
- Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. (2010) (14)
- Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. (1996) (14)
- Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. (2008) (14)
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (2019) (14)
- Breast Cancer (2023) (14)
- Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer (2021) (14)
- Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. (2015) (14)
- Temporal and spatial topography of cell proliferation in cancer (2021) (14)
- Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG (2005) (13)
- Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503) (2017) (13)
- Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab (2016) (13)
- Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer (2017) (13)
- Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. (2001) (13)
- Prospective clinical experience with research biopsies in breast cancer patients (2013) (13)
- The global landscape of treatment standards for breast cancer. (2021) (13)
- Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 (2019) (13)
- 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial (2020) (13)
- Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) (2016) (13)
- Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. (2006) (13)
- Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. (2010) (13)
- Clinical differences among the aromatase inhibitors. (2003) (13)
- Research guidelines. (1995) (12)
- Timeliness in Breast Cancer Treatment-The Sooner, the Better. (2016) (12)
- Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States (2018) (12)
- Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial. (2005) (12)
- Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. (2021) (12)
- A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). (2012) (12)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). (2014) (12)
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). (2020) (12)
- Implementing an interdisciplinary governance model in a comprehensive cancer center. (2007) (12)
- Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer (2013) (12)
- Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. (2014) (12)
- A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. (2013) (12)
- A review of hereditary breast cancer: from screening to risk factor modification. (1997) (12)
- Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study (2021) (12)
- Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. (2019) (12)
- Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors (2005) (12)
- Informed consent for BRCA1 and BRCA2 testing. (1998) (12)
- Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction (2013) (12)
- Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). (2015) (11)
- Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. (2018) (11)
- Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond (2020) (11)
- Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. (2019) (11)
- TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). (2010) (11)
- Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis (2007) (11)
- TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. (2019) (11)
- 796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support (1997) (11)
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? (2013) (11)
- Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. (2012) (11)
- Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. (2012) (11)
- Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study (2021) (11)
- Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer (2021) (10)
- Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference (2008) (10)
- Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer (2021) (10)
- A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC). (2020) (10)
- Blood Vessel Morphological Changes as Visualized by MRA During Treatment of Brain Metastases: A Feasibility Study (2009) (10)
- Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) (2016) (10)
- Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. (2021) (10)
- Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). (2018) (10)
- Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl induced leukemia (2014) (10)
- Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer (2020) (10)
- P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy. (2011) (10)
- Ovarian suppression for breast cancer: an effective treatment in search of a home. (2005) (10)
- IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2018) (10)
- breast cancer, locally advanced and metastaticFirst-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) (2016) (10)
- An FDA Analysis of Survival Outcomes Comparing an Adjuvant Paclitaxel and Trastuzumab Trial to an External Control from Historical Clinical Trials. (2020) (9)
- Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab (2018) (9)
- Breast cancer: noninvasive and special situations. (2010) (9)
- Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). (2021) (9)
- Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. (2012) (9)
- Lumping versus splitting: the splitters take this round. (2002) (9)
- Reducing disparities in breast cancer care: a daunting but essential responsibility. (2008) (9)
- Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) (2021) (9)
- Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302) (2017) (9)
- Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer (2010) (9)
- Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial (2020) (9)
- Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study (2020) (9)
- Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). (2017) (9)
- The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. (2019) (9)
- Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center (2020) (9)
- Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival (2015) (9)
- VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up (2022) (9)
- 215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2017) (9)
- Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? (2012) (8)
- Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab (2020) (8)
- Presentation of breast cancer in young women. (2016) (8)
- Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study (2010) (8)
- Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer (2018) (8)
- Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations (2021) (8)
- Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. (2013) (8)
- CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907 (2008) (8)
- P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial. (2011) (8)
- Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference (2011) (8)
- Ten years of HER2-directed therapy: still questions after all these years (2008) (8)
- A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. (2019) (8)
- Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer (2018) (8)
- Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. (2009) (8)
- Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study (2015) (8)
- Tumor subtypes and survival in male breast cancer (2021) (7)
- Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases (2022) (7)
- Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) (2017) (7)
- Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (2020) (7)
- Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). (2014) (7)
- A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer (2022) (7)
- A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). (2017) (7)
- Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148). (2009) (7)
- Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. (2015) (7)
- A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer (2008) (7)
- Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature (2015) (7)
- Dose density in breast cancer: a simple message? (2005) (7)
- Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer (2022) (7)
- Abstract S5-05: Impact of pre-operative exercise on breast cancer gene expression (2017) (7)
- Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 (2021) (7)
- Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. (2022) (7)
- Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. (2022) (7)
- PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC). (2011) (7)
- The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401). (2018) (6)
- Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR) (2021) (6)
- Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC). (2021) (6)
- Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) (2015) (6)
- Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study (2019) (6)
- Combination inhibition of PI 3 K and mTORC 1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER 2-positive breast cancer brain metastases (2016) (6)
- Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. (2014) (6)
- Surgical Complications and the Use of Neoadjuvant Bevacizumab. (2009) (6)
- A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease (2004) (6)
- Predicting breast cancer therapeutic response (2018) (6)
- Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 (2015) (6)
- Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) (2020) (6)
- Cardiovascular safety of adjuvant bevacizumab for breast cancer. (2010) (6)
- A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. (2013) (6)
- Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study (2007) (6)
- ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. (2021) (6)
- Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) (2022) (6)
- Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions (2005) (6)
- Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance) (2018) (6)
- A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. (2004) (6)
- Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. (2022) (6)
- A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer (2014) (6)
- Breast cancer: T-DM1 — an important agent in the history of breast cancer management (2017) (6)
- Further progress in HER2-directed therapy. (2012) (6)
- A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer (2007) (6)
- A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. (2019) (6)
- Optimal use of aromatase inhibitors: to lead or to follow? (2007) (6)
- A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer (2015) (6)
- Follow-up care of breast cancer survivors. (2003) (6)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
- Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density. (2006) (6)
- Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106) (2021) (5)
- Aggressive Subsets of Metastatic Triple Negative Breast Cancer. (2020) (5)
- Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) (2022) (5)
- Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases (2012) (5)
- ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer. (2018) (5)
- Coping strategies in young women with breast cancer. (2010) (5)
- Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V (2005) (5)
- BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma (2022) (5)
- Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. (2014) (5)
- Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial (2017) (5)
- Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer (2019) (5)
- Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. (2009) (5)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (5)
- Amifostine and chemoradiation therapy: ASCO responds. (2003) (5)
- Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA) (2008) (5)
- Phase II study of ruxolitinib in patients with pStat3+ breast cancer. (2013) (5)
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement (2006) (5)
- Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer (2015) (5)
- Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer. (2014) (5)
- Personalization of loco-regional care for primary breast cancer patients (part 2). (2015) (5)
- Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. (2019) (5)
- Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy (2012) (5)
- A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. (2012) (5)
- Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). (2019) (5)
- Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study (2012) (5)
- Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference (2012) (5)
- RESPONSE: Re: Adherence to Therapy With Oral Antineoplastic Agents (2002) (5)
- Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry (2021) (5)
- Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. (2021) (5)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (5)
- Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort. (2012) (4)
- Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage breast cancer (2001) (4)
- Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2016) (4)
- Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM) (2022) (4)
- ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer (2019) (4)
- Personalization of loco-regional care for primary breast cancer patients (part 1). (2015) (4)
- A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2019) (4)
- A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). (2015) (4)
- Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer (2013) (4)
- Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance) (2019) (4)
- Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? (2021) (4)
- Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care? (2010) (4)
- The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. (2011) (4)
- The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers (2022) (4)
- Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. (2021) (4)
- Genomic features of rapid versus late relapse in triple negative breast cancer (2021) (4)
- Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort (2017) (4)
- TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. (2010) (4)
- Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19 (2021) (4)
- De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ-Reply. (2020) (4)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). (2013) (4)
- Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer (2022) (4)
- Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. (2020) (4)
- Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). (2019) (4)
- Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2015) (4)
- Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. (2011) (4)
- 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases (2020) (4)
- Abstract P6-12-12: Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC) (2017) (4)
- 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- PARP Inhibition: “Targeted” Therapy for Triple Negative Breast Cancer (2010) (4)
- Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. (2016) (3)
- Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases (2017) (3)
- Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance) (2021) (3)
- Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies (2018) (3)
- Abstract P3-06-24: Brief exposure to trastuzumab prior to preoperative chemotherapy confirms predictors of response to treatment (2015) (3)
- Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. (2015) (3)
- Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. (2009) (3)
- Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries (2019) (3)
- Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. (2009) (3)
- A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis. (2018) (3)
- Biomarkers of amenorrhea and ovarian function in breast cancer survivors. (2012) (3)
- Abstract CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer (2015) (3)
- Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119 (2021) (3)
- Abstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer (2021) (3)
- p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases (2022) (3)
- 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer (2020) (3)
- Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL (2011) (3)
- Abstract P4-10-04: EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer (2018) (3)
- Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer (1999) (3)
- Genomic landscape of de novo stage IV breast cancer. (2019) (3)
- Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC) (2020) (3)
- P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer. (2011) (3)
- Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. (2021) (3)
- The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. (2019) (3)
- Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer (2015) (3)
- A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. (2015) (3)
- Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). (2013) (3)
- Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer (2021) (3)
- Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer (2022) (3)
- TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) (2019) (3)
- A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. (2014) (3)
- Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). (2016) (3)
- A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer. (2014) (3)
- Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) (2020) (3)
- Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer. (2006) (3)
- Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCAcarriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031) (2020) (3)
- Edinburgh Research Explorer Personalisation of radiotherapy for breast cancer (2016) (3)
- Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). (2013) (3)
- Attitudes of patients with metastatic breast cancer toward research biopsies. (2013) (3)
- Mammography in Older Breast Cancer Survivors: Can We Ever Stop? (2017) (3)
- Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? (2012) (3)
- A phase I dose-escalation trial of radiation therapy and concurrent cisplatin for stage II and III triple-negative breast cancer. (2021) (3)
- Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers (2022) (3)
- Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial (2010) (3)
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022) (3)
- Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD) (2019) (3)
- Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer (2015) (3)
- Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study (2018) (3)
- Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (2018) (3)
- Genomic features of rapid versus late relapse in triple negative breast cancer (2021) (3)
- A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC. (2018) (3)
- Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (3)
- Symptom burden and employment status in breast cancer (BC) survivors. (2018) (3)
- Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033) (2020) (3)
- Fertility outcomes in young women with breast cancer: A Web-based survey. (2004) (3)
- Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer. (2012) (3)
- Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). (2012) (3)
- Abstract S2-6: Aromatase Inhibitors and Risk of Myocardial Infarction, Stroke and Fracture (2010) (3)
- P53 Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis (1998) (3)
- Factors associated with late risks of breast cancer-specific mortality in the SEER registry (2021) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). (2011) (2)
- Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC) (2021) (2)
- Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) (2017) (2)
- Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. (2010) (2)
- Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer (2019) (2)
- P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). (2011) (2)
- Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors. (2017) (2)
- Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future (2006) (2)
- Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. (2020) (2)
- Abstract P3-09-10: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC) (2020) (2)
- Machine learning predicts rapid relapse of triple negative breast cancer (2019) (2)
- Pharmaceutical involvement in breast cancer clinical trials (2005) (2)
- Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer. (2013) (2)
- Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models (2021) (2)
- Decisional Regret Scale (2013) (2)
- Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2021) (2)
- Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer (2021) (2)
- A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer. (2015) (2)
- Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP). (2022) (2)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
- Fertility concerns in young women with breast cancer: Results from a prospective cohort study. (2011) (2)
- Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery (2021) (2)
- Adjuvant ovarian suppression in premenopausal breast cancer | NOVA. The University of Newcastle's Digital Repository (2015) (2)
- Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study (2018) (2)
- Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer. (2009) (2)
- Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study (2020) (2)
- Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER (2021) (2)
- S39 Treatment of postmenopausal women with hormone responsive breast cancer (2009) (2)
- Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. (2012) (2)
- The impact of an exercise intervention on body composition, fat distribution, and weight in breast cancer survivors. (2006) (2)
- Perceptions of patients with early stage breast cancer toward research biopsies (2020) (2)
- Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. (2006) (2)
- Abstract P3-10-15: Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer (2010) (2)
- A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC). (2015) (2)
- Superiority of bi-dimensional measurements compared to RECIST in measuring response of metastatic brain tumors. (2006) (2)
- Adjuvant hormonal therapy for postmenopausal women (2007) (2)
- 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741 (2012) (2)
- OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. (2011) (2)
- Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. (2007) (2)
- Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations (2014) (2)
- Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2018) (2)
- Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort. (2015) (2)
- Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer (2001) (2)
- The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer (2022) (2)
- The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention (2021) (2)
- Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer (2018) (2)
- Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840 (2005) (2)
- REVIEW Adherence to Therapy With Oral Antineoplastic Agents (2002) (2)
- IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (2)
- Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. (2017) (2)
- Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515). (2013) (2)
- Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. (2022) (2)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. (2023) (2)
- Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. (2022) (2)
- Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials (2022) (2)
- Impact of physical activity on insulin levels in breast cancer survivors (2007) (2)
- Use and duration of chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy (tx). (2012) (2)
- Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer (2017) (2)
- POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. (2015) (2)
- NI-23BRAIN BREAST METASTASES RESPOND TO ANTI-ANGIOGENIC THERAPY BY MODES OF VASCULAR NORMALIZATION (2014) (2)
- Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. (2011) (2)
- Rebeccamycin analog for refractory breast cancer: a randomized phase II trial (2004) (2)
- Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer (2017) (2)
- Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study (2022) (1)
- Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab (2018) (1)
- Therapy for HER2-Positive Metastatic Breast Cancer. Reply. (2020) (1)
- Adjuvant chemotherapy for older patients with breast cancer: When is the pain worth the gain? (2020) (1)
- Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases (2021) (1)
- P-166: Chemotherapy-related amenorrhea in premenopausal women with breast cancer: The effect of paclitaxel, dose density and trastuzumab (2006) (1)
- Abstract PD3-01: Immune profile of small HER2+ tumors in the APT trial (2018) (1)
- Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. (2009) (1)
- Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy (2012) (1)
- POINT : HER 2-Targeted Combinations in Advanced HER 2-Positive Breast Cancer (2017) (1)
- Comment on: Adherence to therapy with oral antineoplastic agents. Authors' reply (2002) (1)
- PL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics. (2011) (1)
- Abstract P6-09-10: All-cause survival estimates compared to observed survival in older women with breast cancer in CALGB 49907 and 369901 (Alliance A151503) (2016) (1)
- Abstract 4564: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab (2018) (1)
- Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. (2009) (1)
- The Evolving Role of Adjuvant Chemotherapy. (2009) (1)
- A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial (2022) (1)
- Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527. (2016) (1)
- Characterization of mutational processes in ER+ metastatic breast cancer. (2019) (1)
- A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. (2009) (1)
- Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907). (2009) (1)
- Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 ) (2011) (1)
- ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. (2017) (1)
- Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) (2019) (1)
- Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction. (2013) (1)
- Personalized treatment of breast cancer (2016) (1)
- Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis (2022) (1)
- Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. (2016) (1)
- A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer (2022) (1)
- A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. (2016) (1)
- Abstract P6-08-03: Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis (2012) (1)
- Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC). (2021) (1)
- Abstract P5-12-02:PTENalterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) (2019) (1)
- TransCONFIRM : Identi fi cation of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor – Positive Breast Cancer (2016) (1)
- Abstract CT011: Circulating tumor DNA (ctDNA) sequencing forHER2mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC) (2017) (1)
- 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) (2021) (1)
- Factors associated with non use of adjuvant trastuzumab in older patients with HER2+ breast cancer. (2016) (1)
- E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting (2012) (1)
- Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. (2017) (1)
- Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515) (2012) (1)
- Abstract GS3-07: Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA (2018) (1)
- Abstract P3-10-13: Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer (2010) (1)
- Local-Regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial) (2017) (1)
- 5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib (2009) (1)
- Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. (2010) (1)
- Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer (2021) (1)
- Predicting the Risk of Axillary Nodal Metastases and Their Use in Selecting Breast Surgery Options (2009) (1)
- Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). (2013) (1)
- Abstract CT271: PRECISION (Profiling early breast cancer for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer (2020) (1)
- CCR Drug Updates Pertuzumab : Optimizing HER 2 Blockade (2013) (1)
- Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC). (2014) (1)
- A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. (2013) (1)
- Predictors of survival in patients with HER2+ metastatic breast cancer (MBC) treated with trastuzumab. (2011) (1)
- Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. (2023) (1)
- Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer andBRCA1/2mutations (2019) (1)
- Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance) (2018) (1)
- Abstract P1-08-07: Predisposing germline mutations in a clinic based breast cancer (BC) population (2016) (1)
- P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors. (2011) (1)
- Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC) (2012) (1)
- Abstract P5-10-12: Adherence, Persistence and Toxicity with Oral CMF in Older Women with Early Stage Breast Cancer in CALGB 49907 (Adherence Companion Study 60104) (2010) (1)
- Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study (2021) (1)
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
- Abstract OT2-3-06: A phase II, non-randomized, multicenter, exploratory trial of single agent BKM120 in patients with triple-negative metastatic breast cancer. (2012) (1)
- P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen. (2011) (1)
- Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy (2022) (1)
- A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB (2018) (1)
- TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. (2014) (1)
- Abstract P4-17-01: Attitudes of medical oncologists towards research breast biopsies in patients with newly diagnosed stage I-III breast cancer not enrolled in a clinical trial (2015) (1)
- Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. (2013) (1)
- Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer (2019) (1)
- Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer. (2020) (1)
- Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) (2017) (1)
- Impact of a home-based physical activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer. (2009) (1)
- Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study. (2015) (1)
- Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. (2018) (1)
- Local and systemic management of primary breast cancers (2010) (1)
- Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2017) (1)
- A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). (2017) (1)
- Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) (2022) (1)
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR 1 Activating Mutations Graphical Abstract Highlights (2018) (1)
- Will preoperative trials change future clinical practice (2011) (1)
- Adjuvant and neoadjuvant therapy in patients with early breast cancer: Principles and practical considerations (2019) (1)
- 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) (2022) (1)
- Abstract P2-15-01: Long-Term Risk Perceptions and Quality of Life of Women with Ductal Carcinoma In Situ (2010) (1)
- Abstract P6-15-11: Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer (2018) (1)
- 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB) (2020) (1)
- A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC). (2018) (1)
- 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation (2020) (1)
- A phase II study of ixabepilone and trastuzumab for metastatic HER 2-positive breast cancer (2013) (1)
- Q&A: Eric Winer on neoadjuvant clinical trials. (2013) (1)
- A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. (2014) (1)
- Abstract P1-05-13: The metastatic breast cancer project: Translational genomics through direct patient engagement (2017) (1)
- Abstract ES9-3: Adjuvant and neoadjuvant therapy: Current practice and future approaches (2015) (1)
- Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342 (2005) (1)
- P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype. (2011) (1)
- Abstract P4-01-17: Aggressive subgroups of metastatic triple-negative breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort (2019) (1)
- Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease (2013) (1)
- Racial disparity trends in definitive primary therapy of early stage breast cancer (2008) (1)
- Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years. (2000) (1)
- Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. (2022) (0)
- IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC (2019) (0)
- Abstract P2-18-02: Factors associated with contralateral prophylactic mastectomy in young women with breast cancer (2013) (0)
- Subject Index Vol. 64, 2003 (2003) (0)
- Erratum: Long‐term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer (2007) (0)
- 87 INVITED Neoadjuvant antiHER2 therapy (2007) (0)
- OP-ANNO180192 1634..1657 (2018) (0)
- Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer (2013) (0)
- Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies (2015) (0)
- Accuracy of risk perceptions of women with ductal carcinoma in situ (2004) (0)
- Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer (2012) (0)
- Survival in male breast cancer over the past three decades. (2022) (0)
- Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. (2016) (0)
- Recommendations to Promote Caregiver Wellbeing: Perspectives from Family Caregivers of Ambulatory Patients with Newly Diagnosed Advanced Cancer (RP415) (2022) (0)
- Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer (2006) (0)
- Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM) (2023) (0)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (0)
- Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2021) (0)
- Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. (2023) (0)
- Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer (2023) (0)
- Abstract PD7-07: Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis (2023) (0)
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022) (0)
- A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer (2022) (0)
- A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer (2018) (0)
- Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer. (2022) (0)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (0)
- Abstract PD6-08: PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer (2023) (0)
- Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 (2023) (0)
- Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer (2018) (0)
- Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer (2019) (0)
- Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer (2023) (0)
- Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx (2022) (0)
- Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast Cancer (MBC) (2023) (0)
- Abstract OT1-12-02: Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer (2023) (0)
- Abstract PD18-02: Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: final 10-year analysis (2023) (0)
- P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer. (2011) (0)
- Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) (2023) (0)
- PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer (2019) (0)
- Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) (2017) (0)
- Neratinib Ef fi cacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonampli fi ed Metastatic Breast Cancer (2017) (0)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (0)
- Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors (2023) (0)
- Abstract P4-18-01: Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group (2013) (0)
- TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM) (2019) (0)
- Abstract PD12-01: PD12-01 Impact of obesity and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019 (2023) (0)
- Delivering bad news: the importance of involving family members (1998) (0)
- TITLE: Sensitive detection of minimal residual disease in patients treated for early- 1 stage breast cancer 2 (2020) (0)
- Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab andnab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial (2021) (0)
- The use of adjuvant chemotherapy for breast cancer in a community practice. (1985) (0)
- Abstract P1-07-08: Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma, a population-based study (2016) (0)
- Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy (2017) (0)
- Abstract PR06: Racial/ethnic differences in breast cancer survival and mediating effects of tumor characteristics, sociodemographic, and treatment factors. (2012) (0)
- Abstract P2-08-07: Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER+/HER2- breast cancer (2019) (0)
- Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial) (2013) (0)
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. (2021) (0)
- P2-19-02: Multidisciplinary Treatment of Pregnancy-Associated Breast Cancer. (2011) (0)
- Abstract 337: p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases (2021) (0)
- Aromatase Inhibitors for Breast Cancer Treatment and Prevention: Section III: Novel Therapies and Treatment (2007) (0)
- Clinical differences among the aromatase inhibitors. Discussions (2003) (0)
- Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study (2015) (0)
- Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review (2023) (0)
- Abstract P5-06-13: Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) for locally-advanced breast cancer (LABC) in the surveillance, epidemiology, and end results (SEER) registry (2020) (0)
- Abstract P3-07-31: Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy (2016) (0)
- Nonadherence t o A djuvant T amoxifen T herapy i n W omen W ith Primary B reast C ancer (2003) (0)
- Genetic testing in young women with breast cancer: Results from a web-based survey (2007) (0)
- Abstract PD4-08: An FDA analysis of survival outcomes comparing adjuvant paclitaxel and trastuzumab trial (APT) to an external control from historical clinical trials (2020) (0)
- Optimizing Endocrine Therapy for Breast Cancer: 'Miles to Go' (2007) (0)
- Metastatic Breast Cancer Session (2008) (0)
- Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study. (2019) (0)
- Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance). (2013) (0)
- Reply to V. Amoroso et al. (2015) (0)
- Abstract P4-06-01: Using multi-omic profiling to unravel the complexity of triple-negative breast cancer (TNBC) (2020) (0)
- Whole exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). (2015) (0)
- HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). (2011) (0)
- Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer (2022) (0)
- Abstract OT1-1-07: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer (2013) (0)
- Deriving biomarkers using brief-exposure to trastuzumab in HER2 + breast cancer (2010) (0)
- 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC (2016) (0)
- Implementation of team training in outpatient breast oncology. (2012) (0)
- The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. (2008) (0)
- Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases (2020) (0)
- Contents Vol. 64, 2003 (2003) (0)
- Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study. (2016) (0)
- Changes i n W eight, B ody C omposition, a nd F actors Influencing E nergy B alance A mong P remenopausal B reast Cancer P atients R eceiving A djuvant C hemotherapy (2001) (0)
- Cancer esearch ew ( ADP-Ribose ) Polymerase Inhibition : “ Targeted ” Therapy R Triple-Negative Breast Cancer (2010) (0)
- Current Chal lenges in HER 2-pos i t ive Breast Cancer (0)
- Reply to S. Sorscher. (2017) (0)
- A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). (2015) (0)
- P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003. (2011) (0)
- Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study. (2015) (0)
- SYST-06. PHASE II TRIAL OF PAXALISIB (GDC-0084) IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM) (2021) (0)
- Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis (2011) (0)
- OR34 Sexual functioning in young women with breast cancer (2012) (0)
- Use of experimental therapy outside of clinical trials among U.S. oncologists. (2006) (0)
- Reply to S. Mahesh (2012) (0)
- Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. (2004) (0)
- A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC) (2019) (0)
- A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance). (2018) (0)
- Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial (2022) (0)
- Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutations (2021) (0)
- Overcoming Therapeutic R esistance in HER 2-Positive Breast Cancers with CDK 4 / 6 Inhibitors Highlights (2016) (0)
- Adjuvant endocrine therapy in postmenopausal breast cancers. Discussions (2003) (0)
- 5025 POSTER DISCUSSION Phase 3 Study of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) – Results of an Exploratory Analysis by Prior Therapy (2011) (0)
- Reply to E. Warner (2012) (0)
- Abstract P3-10-08: A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC) (2020) (0)
- Abstract P4-19-01: Attitudes of medical oncologists towards research biopsies (2013) (0)
- Genomic profiling of breast cancer brain metastases reveals targetable alterations. (2020) (0)
- Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research (2016) (0)
- Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy (2015) (0)
- Quality o f N on-Breast C ancer H ealth M aintenance A mong Elderly B reast C ancer S urvivors (2003) (0)
- Abstract P1-04-05: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial (2023) (0)
- Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment (2020) (0)
- Abstract PD07-08: Integrated Genomic Analysis before and after Brief Exposure to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer (2010) (0)
- The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. (2018) (0)
- Introducing Breast Cancer Research's updates on clinical trials (2004) (0)
- Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance). (2013) (0)
- Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). (2016) (0)
- Abstract OT1-08-05: Phase II trial of GDC-0084 in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases (BCBM) (2020) (0)
- HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). (2011) (0)
- Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx). (2015) (0)
- Phase I I E valuation o f T halidomide i n P atients W ith Metastatic B reast C ancer (2000) (0)
- Abstract A14: Cellular immunotherapy for refractory hematological malignancies: Haploidentical donor lymphocyte infusions generate an allogeneic effect that targets leukemia. (2015) (0)
- Commentary (Spigel/Winer): Myalgias and Arthralgias Associated With Paclitaxel (2003) (0)
- Abstract LB-350: Abelson interactor-1 (Abi1) expression levels as a prognostic and drug resistance marker in Bcr-Abl positive leukemias. (2013) (0)
- Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial (2022) (0)
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies (2018) (0)
- Quality of life and psychosocial distress in young women with advanced breast cancer. (2013) (0)
- Abstract P2-16-04: Attitudes of metastatic breast cancer patients towards research biopsies (2012) (0)
- Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (2020) (0)
- Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet ! (2003) (0)
- Molecular predictors of response to fulvestrant 1 TransCONFIRM : Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer (2016) (0)
- Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design (2017) (0)
- Concordance Between Outside Laboratory Immunohistochemistry Results and Fluorescence In Situ Hybridization ( FISH ) Results from a Central Laboratory (2007) (0)
- Abstract P2-10-01: Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with triple-negative breast cancer (2022) (0)
- Randomized Trial of Asprin as Adjuvant Therapy for Node-Positive Breast Cancer (2016) (0)
- Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. (2017) (0)
- Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts). (2016) (0)
- Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545 (2020) (0)
- Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer (2022) (0)
- Abstract 1881: Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy (2012) (0)
- ONCOLOGY NURSES ATTITUDES AND PRACTICES ABOUT INFORMING CLINICAL TRIALS PARTICIPANTS OF STUDY RESULTS (2011) (0)
- The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. (2003) (0)
- Study participants' perceptions of the process and impact of receiving results of N9831. (2006) (0)
- Disparities among older women with de novo stage IV breast cancer treated with trastuzumab from 1999 to 2009. (2014) (0)
- Should there be guidelines for the treatment of metastatic breast cancer: the U.S. perspective (2006) (0)
- Clinical A ctivity o f T rastuzumab a nd V inorelbine i n Women W ith H ER2-Overexpress ing M etastatic B reast Cancer (2001) (0)
- Abstract P2-13-03: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions (2015) (0)
- Adjuvant Chemotherapy in Breast Cancer (2015) (0)
- Implementation of a team training program in the treatment of breast cancer patients. (2012) (0)
- Prospective clinical experience with research biopsies in breast cancer patients. (2013) (0)
- Abstract P1-07-05: Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and poor prognosis (2017) (0)
- Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC). (2012) (0)
- Abstract P1-15-01: Withdrawn (2019) (0)
- Predicting breast cancer therapeutic response (2018) (0)
- PG 12.01 Tailoring the chemotherapy regimen in patients with triple negative subtypes (2015) (0)
- Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. (2015) (0)
- Use of discard pleural fluid in molecular research (2012) (0)
- Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations (2020) (0)
- Abstract P6-19-02: Tumor subtypes and survival in male breast cancer: SEER 2010-2014 (2019) (0)
- Abstract OT1-01-09: Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen (2017) (0)
- Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119 (2021) (0)
- Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumors (2011) (0)
- Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC) (2020) (0)
- Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer? (2010) (0)
- JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines (2006) (0)
- Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) (2021) (0)
- Factor V l eiden Mutation and t hromboembolism r isk in Women r eceiving Adjuvant t amoxifen for Breast c ancer (2010) (0)
- Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age. (2009) (0)
- Cancer-Related Communication Problems Within Couples Scale (2017) (0)
- Expanding criteria for prognostic stage IA disease in HR+ breast cancer. (2020) (0)
- Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2019) (0)
- Comprar Personalized Treatment Of Breast Cancer | Masakazu Toi | 9784431555513 | Springer (2016) (0)
- Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer (2001) (0)
- Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice (2019) (0)
- Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study (2018) (0)
- Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev). (2017) (0)
- P4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men. (2011) (0)
- Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study (2019) (0)
- Corticosteroids Plus Intravenous Immune Globulin (IVIg) Versus Corticosteroids Alone In The Treatment Of Newly Diagnosed Primary Immune Thrombocytopenia In Adults: A Retrospective Study (2013) (0)
- Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer (2017) (0)
- Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance. (2015) (0)
- Heterogeneity, Genome Complexity of TNBC Complicate Therapy (2014) (0)
- Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) (2013) (0)
- Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy? (2017) (0)
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (0)
- Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. (2023) (0)
- PD09-04: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer. (2011) (0)
- Phase I Trial Examining Addition of Gemcitabine to CHOP in Intermediate Grade NHL. (2009) (0)
- Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer (2022) (0)
- Abstract B23: Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors (2020) (0)
- First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results. (2019) (0)
- Randomized trial of a physical activity intervention in patients with metastatic breast cancer. (2012) (0)
- Sexual functioning in young women with breast cancer. (2012) (0)
- Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer (2018) (0)
- Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer (2015) (0)
- Correction to: Factors associated with late risks of breast cancer‑specific mortality in the SEER registry (2021) (0)
- Roundtable discussion: Current standard of care for adjuvant hormonal treatment of breast cancer (2005) (0)
- Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance). (2019) (0)
- PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery. (2011) (0)
- Abstract P4-05-02: Machine learning predicts rapid relapse in triple negative breast cancer (2020) (0)
- American S ociety o f C linical O ncology T echnology A ssessment Working G roup U pdate: U se o f A romatase I nhibitors i n t he Adjuvant S etting (2003) (0)
- Survival in male breast cancer (MaBC) over the past three decades. (2021) (0)
- Notifying Participants of Clinical Trial Results—Reply (2002) (0)
- Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC) (2013) (0)
- Urokinase-type plasminogen activator gene (PLAU) to predict clinical outcome in invasive lobular carcinoma. (2012) (0)
- Hydrocortisone W ith o r W ithout M itoxantrone i n M en W ith Hormone-Refractory P rostate C ancer: R esults o f t he C ancer and L eukemia G roup B 9 182 S tudy (1999) (0)
- Abstract 4719: Dynamic changes in gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancer (2011) (0)
- Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases (2020) (0)
- Reply to M. Tanaka et al. (2021) (0)
- Accuracy of risk perceptions of women with ductal carcinoma in situ. (2004) (0)
- Modulation of 06-Alkylguanine-DNA Alkyltransferase-mediated Carmustine Resistance Using Streptozotocin: A Phase I Trial1 (2006) (0)
- Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism (2008) (0)
- Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer (2016) (0)
- Abstract P4-01-02: Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancer (2015) (0)
- Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
- Abstract P2-07-03: Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancer (2022) (0)
- A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM). (2018) (0)
- Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts). (2013) (0)
- Impact of PST on Pathologic Response and Survival in Breast Cancer (2014) (0)
- Proton Pump Inhibitor Use and the Ability to Replete Iron Stores (2011) (0)
- Anatomy Versus Biology: To What Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy? (2007) (0)
- Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer (2022) (0)
- Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences (2016) (0)
- Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial (2022) (0)
- Abstract P6-05-05: Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC) (2023) (0)
- Consultation W ith a M edical O ncologist B efore S urgery a nd Type o f S urgery A mong E lderly W omen W ith E arly-Stage Breast C ancer (2003) (0)
- Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant (2015) (0)
- Abstract 2836: A discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and T (2015) (0)
- S15 Role of baseline staging and follow-up: between reassurance and economic constraints (2007) (0)
- Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings (2022) (0)
- State of the Art Treatment of Triple Negative Breast Cancer (2011) (0)
- Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo (2013) (0)
- Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer (2015) (0)
- ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer. (2019) (0)
- Abstract PS6-13: Population-based tool to estimate residual risks of breast cancer specific mortality (BCSM) and non-BCSM (2021) (0)
- Characterization of PI3KCA Mutation in Lobular Breast Cancer. (2012) (0)
- Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907 (2012) (0)
- A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. (2016) (0)
- Quality of care for metastatic breast cancer (MBC). (2016) (0)
- OP-JNCI200081 1..5 (2020) (0)
- Introduction: late effects of treatment and surviorship issues in early-stage breast carcinoma (2003) (0)
- Abstract P2-15-03: A Phase Ib Study of an adjuvant GM-CSF-Secreting Breast Cancer Vaccine (2015) (0)
- The Legacy of Professor Aron Goldhirsch. (2020) (0)
- Proceedings from an Interactive Case-Based Symposium on the Management of Patients with Early and Advanced Breast Cancer (2012) (0)
- Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer (2020) (0)
- Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer (2019) (0)
- Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. (2009) (0)
- A phase I study of an autologous GM-CSF-secreting breast cancer vaccine. (2009) (0)
- Abstract P3-14-08: Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer (2010) (0)
- Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity. (2009) (0)
- Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state (2020) (0)
- Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. (2022) (0)
- Adjuvant therapy of HER2+ breast cancer (2009) (0)
- PCN13 SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA (2010) (0)
- Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 (2023) (0)
- Abstract B04: CDK4/6 inhibition triggers an antitumor immune response (2018) (0)
- Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (2019) (0)
- Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. (2019) (0)
- Abstract P5-13-15: High dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapy (2022) (0)
- 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (0)
- Edinburgh Research Explorer Tucatinib, Trastuzumab and Capecitabine for HER2+ Metastatic Breast Cancer (2019) (0)
- ASO Visual Abstract: Expanding Staging Criteria in T1–2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx (2022) (0)
- Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. (2021) (0)
- Restaurant booth unit orsimilar article (1967) (0)
- Abstract OT2-5-02: Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer (2013) (0)
- Targeting HER2 in breast cancer: beyond trastuzumab (2011) (0)
- Abstract PD13-10: Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors (2022) (0)
- Abstract PD9-01: Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial (2022) (0)
- PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. (2011) (0)
- Abstract MS02-1: HER2+ breast cancer: Unresolved challenges (2013) (0)
- Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04 (2018) (0)
- Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer (2019) (0)
- Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer (2006) (0)
- Adjuvant endocrine therapy for pre- and postmenopausal women (2021) (0)
- Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER (2017) (0)
- Abstract ES7-1: Progression of Disease and End of life: How to Break Bad News (2020) (0)
- Reply to A.K. Goel et al. (2019) (0)
This paper list is powered by the following services:
Other Resources About Eric Winer
What Schools Are Affiliated With Eric Winer?
Eric Winer is affiliated with the following schools:
- University of Washington
- Harvard University
- Heidelberg University
- University of Vermont
- Medical University of Vienna
- Indiana University
- MD Anderson Cancer Center
- University of Michigan
- Riken
- University of California, Los Angeles
- University of Glasgow
- Massachusetts General Hospital
- New York University
- Duke University
- Université libre de Bruxelles
- Brown University
- Washington University in St. Louis
- McGill University
- Indiana University Bloomington
- University of Milan
- Yale University
- Ohio State University
- Tel Aviv University
- Stanford University
